01 1TEGSEDI and WAYLIVRA revenue, net
02 3Tegsedi
03 2Tegsedi and Waylivra Revenue, Net
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2021 Revenue in Millions : 56
2020 Revenue in Millions : 70
Growth (%) : -21
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2021 Revenue in Millions : 46
2020 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2022 Revenue in Millions : 30
2021 Revenue in Millions : 56
Growth (%) : -46
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2023 Revenue in Millions : 35
2022 Revenue in Millions : 30
Growth (%) : 16
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2022 Revenue in Millions : 40
2021 Revenue in Millions : 46
Growth (%) : -12
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2023 Revenue in Millions : 29
2022 Revenue in Millions : 40
Growth (%) : -29
LOOKING FOR A SUPPLIER?
